Targeting NOS1 either through Hsp90 inhibitors to block its mitochondrial localization or via specific inhibitors such as Nω-propyl-L-arginine may offer dual benefits: mitigating therapy resistance and addressing metabolic risk factors in CRC (57, 58). This evidence concerns the gene NOS1 and colorectal carcinoma.